Benzinga | Nov 4, 2021 07:31AM EDT

Ironwood Pharmaceuticals Announces It Will Expand Its Pipeline By Signing An Option Agreement To Acquire An Exclusive License With COUR Pharmaceuticals To Develop And Commercialize CNP-104 For The Treatment Of Primary Biliary Cholangitis In The U.S.

IND for CNP-104 Accepted by FDA; Clinical Trials Planned for the End of 2021

Ironwood to Make a Payment of approximately $20 Million in Upfront and Near-Term Milestones and up to $475 Million in Long-Term Commercial and Regulatory Milestones and Royalties to COUR